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ICS expenditures and use (2003–2004) among Medicare+Choice
beneﬁciaries with asthma, and a high-severity asthma subgroup.
METHODS: We used automated data from an integrated deliv-
ery system in the U.S. All subjects were continuously enrolled,
age 65+, asthma-registry members with prior ICS use, and had
$10 generic-copayments and no chronic obstructive pulmonary
disorder diagnoses or ipratropium bromide use (n = 2,908). In
2004, 74.0% switched from a $30 brand-copayment with a
$1000 annual cap, to generic-only coverage (full-price for brand-
drugs), with no cap; 26.0% had $15–25 brand-copayments
2003–2004 (control-group). We used linear difference-in-differ-
ence models to examine changes (2003–2004) in ICS expendi-
tures (total and out-of-pocket) and use (days-of-supply). Models
adjusted for gender, age, race/ethnicity, neighborhood socioeco-
nomic-status, comorbidity, chronic diseases, and asthma 
characteristics (high-risk asthma-ﬂag, high-dose ICS, prior
asthma-related emergency or hospital visits, oral steroid use, and
ICS type). We deﬁned patients as having high-severity asthma if
they had a high-risk ﬂag or a high-dose ICS prescription (n =
798). RESULTS: In multivariate analyses, patients who lost
brand-coverage had lower total ICS expenditures (−$106,
[95%CI: −$125 to −$87]), but higher out-of-pocket expenditures
($52, [$40 to $64]), compared with patients with no coverage
changes; ICS days-of-supply were also lower (−11.6 days, [−18.5
to −4.8]). Among high-severity asthma patients, loss of brand-
coverage was associated with changes similar in direction, but
larger in magnitude: total ICS expenditures (−$270, [−$322 to 
−$219]); out-of-pocket expenditures ($74, [$43 to $104]); and
days-of-supply (−24.2, [−37.6 to −10.9]). CONCLUSIONS:
Patients with generic-only coverage had higher out-of-pocket
costs and lower total expenditures and days-of-supply for
inhaled corticosteroids. These changes were greater among high-
severity asthma patients. Future research will examine the clini-
cal effects of these changes.
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HEALTH PLAN STRUCTURE AND EXPENDITURES FOR
ASTHMA CARE
Nurmagambetov T,Atherly A,Williams S, Redd S
Centers for Disease Control and Prevention, Atlanta, GA, USA
OBJECTIVES: The objective of this study is to evaluate the effect
of health plan structure on health care utilization and expendi-
tures for asthma care. Some health plans in the USA require a
designated primary care physician (PCP plans) and some do not
(NPCP plans). METHODS: Our data was drawn from the
MEDSTAT MarketScan database. The sample had 330,685
patients with either at least one hospitalization or at least two
outpatient visits for asthma during 1998–2001. Approximately
47% (154,106) of the patients had PCP plans; the remainder had
NPCP health plans. We performed regression analysis to
examine the effect of having a primary care physician and capi-
tation in the health plan on expenditures for asthma, controlling
for gender, age, employment status, and health status via the
Charlson comorbidity index. RESULTS: We found annual per
capita inpatient expenditures for asthma were about 8.4% lower
for the patients in the PCP plans compared to the patients in the
NPCP plans (p < 0.01), with a mean length of stay 0.07 days
shorter (p < 0.01) and 0.02 times fewer admissions (p < 0.01)
per year for asthma. However, annual per capita outpatient
expenditures for asthma were 9.1% higher in the PCP plans com-
pared to the NPCP plans (p < 0.01) as PCP asthma patients
received 1.4 more outpatient services per year (p < 0.01) and
about 0.2 more outpatient visits (p < 0.01) per year than NPCP
asthma patients. On net, total expenditures were 3.2% lower for
PCP asthma patients (p < 0.01) than for NPCP asthma patients.
CONCLUSIONS: For asthma care, there is a tradeoff between
relatively inexpensive outpatient services and more expensive
inpatient services. Results of this study suggest that patients with
asthma enrolled in PCP plans used signiﬁcantly more outpatient
services and fewer inpatient services, resulting in lower overall
spending.
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OBJECTIVE: The study is focused on the potential impacts of
genome-based technologies on health care. We have chosen
asthma in children as a case study and gene-screening as the tech-
nology assessed to explore the cost-effectiveness of applying an
early genetic- screening to newborns and a preventive treatment
to the population at risk. METHODS: A Markov model con-
sisting on six mutually exclusive disease states with a simulation
horizon of 100 years was constructed. Two different scenarios
were deﬁned. RESULTS: In the base case and for scenario 1, the
number of quality adjusted life years (QALY) gained is 4.081
and the incremental cost-effectiveness ratio per QALY gained is
€40416.1/QALY. In scenario 2, the number of QALYs gained is
1.483 and the incremental cost-effectiveness ratio per QALY
gained falls to €18474.27/QALY. We have carried out a sensi-
tivity analysis varying the discount rate, the cost of genetic
testing and considering two different transition matrixes for the
preventive programme. Two main conclusions are derived from
the sensitivity analysis carried out. Firstly, it seems that increas-
ing by 2% the discount rate for both cost and health outcomes
the cost-effectiveness of the preventive programme does not vary
so much. However, discounting costs and beneﬁts at 5% the pre-
ventive programme in both scenarios appears as cost-effective.
Secondly, it seems that increasing the cost of genetic testing up
to 100€ the cost-effectiveness of the preventive programme in
both scenarios remains practically stable. CONCLUSIONS: The
cost-effectiveness of an early genetic-screening and the preven-
tive strategy applied to all populations presenting the selected
ADAM33 remains at the limit of the cost-effectiveness. Never-
theless the model represents a valuable tool to prospectively
assess cost-effectiveness of preventive schemes based on genetic
screening.
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OBJECTIVES: Medication adherence rates (using the MPR)
were assessed among asthmatic patients who are under therapy
with an inhaled long-acting beta2-agonist + corticosteroids
(LABA+ICS) or a ﬁxed ﬂuticasone/salmeterol combination
(FSC).The differences between patients, who stick to their
therapy, compared to those, who switch between different
regimes or agents were analysed. METHODS: Claims data were
drawn from the IMS Database. Patients with asthma (°Y´18
years) who are under inhaled therapy according to the National
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Disease Management Guideline for Germany were identiﬁed.
The percentages of patients who had a switch in medications
were determined. In sub-analyses patients who were new to their
therapy and patients with concomitant (add on) medications
were also assessed. RESULTS: Compared with patients who
received the FSC, those receiving LABA+ICS were more likely to
have a switch in medication (35% versus 26%) and to use add
on medications (54% versus 35%). The highest proportion of
adequately adherent (°Y´70%) patients was among those switch-
ing between medications. About 64% of the FSC cohort showed
good adherence with an average MPR of 72%. In contrast only
15% of the patients using LABA+ICS were adequately adherent
with an average MPR of 31%. Patients continuing to take their
existing FS combination were on average 63% adherent;
however even in this group, only 48% exhibited adequate adher-
ence. The sub-analyses showed that patients who were new to
anti-asthmatic medications had the worst medication adherence
(59% for FSC; 8% for LABA+ICS). Patients with add on med-
ication (as a surrogate for severe asthma) showed a mean MPR
of 74% in the FSC and 39% in the LABA+ICS cohort. CON-
CLUSIONS: The use of the FSC combination was associated
with less treatment switching and less use of concomitant med-
ications. Furthermore the FSC cohort showed a better average
medication adherence and a higher proportion of adequate
adherent patients.
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OBJECTIVES: Population-based norms help in improving inter-
pretation of quality of life (QOL) data. The Esprint-15 ques-
tionnaire is a recently validated QoL questionnaire speciﬁc to
patients with allergic rhinitis (AR). This study was to obtain pop-
ulation reference norms for this new questionnaire. METHODS:
A cross-sectional study was carried out in primary care and spe-
cialized health care centers. The Esprint-15 questionnaire (which
has a global score and 4 dimension scores: symptoms, daily life
activities, sleep and psychological impact) was administered to a
large, heterogeneous sample of AR patients. The sample was
stratiﬁed on four characteristics (sex, age—three groups–, type
of AR—persistent and intermittent deﬁned as recommended in
the ARIA guidelines—, and symptom intensity—asymptomatic,
mild, moderate, severe). This classiﬁcation deﬁned 48 different
proﬁles of patients. Patient inclusion criteria were: over 18 years
old with a clinical diagnosis of AR, and visiting the doctor
because of AR at the time of inclusion in the study. RESULTS:
A total of 2682 AR patients were recruited: 53% women, 51%
with intermitent AR, and symptoms ranged from none or asymp-
tomatic (19%) to moderate (30%). Gender, type of AR and
symptom intensity but not age were associated with QOL scores
and were considered as stratifying variables for the reference
value tables. Mean overall score (standard deviation—SD) for
males was 2.18 (1.35) and for females 2.39 (1.37); mean (SD)
scores for patients with intermittent and persistent AR were 2.13
(1.35) and 2.47 (1.36), respectively. Reference values obtained
were organized in 29 tables, with values presented for each of
the three main variables individually and in combination via
means, standard deviations, medians, interquartile ranges and
decils. CONCLUSIONS: The reference values obtained in this
study will help to improve the interpretation of scores obtained
on the Esprint-15 questionnaire and should be useful in research
and clinical practice.
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OBJECTIVES: Ciclesonide is a novel inhaled corticosteroid (ICS)
for anti-inﬂammatory asthma therapy. Patients’ perception of
ICS-related side effects is not only important for treatment sat-
isfaction but might also have a major impact on compliance. We
used the new self-administered Inhaled Corticosteroid Ques-
tionnaire (ICQ) to compare patient-perceived side effects in a 
12-week, open-label, parallel-group study with ciclesonide or 
ﬂuticasone propionate (FP). METHODS: During the baseline
period (1–4 weeks), patients received either FP ≤ 250 μg/d (or
equivalent) or rescue medication only. Patients (n = 472, inten-
tion-to-treat population; 12–74 years) with FEV1 60–80% pre-
dicted (rescue medication) or ≥80% predicted (low dose ICS) and
deﬁned criteria for rescue medication use and asthma symptoms
were centrally randomized by IVR system to receive either 
320 μg ciclesonide once daily (ex-actuator, HFA-MDI), or 
200 μg FP twice daily (Diskus®). Patients completed the ICQ (57
questions, 7-point scale, 15 domains) at start and end of the
treatment. ICQ data were analysed by non-parametric methods
for differences between ciclesonide and FP. Intention-to-treat
analysis was of primary interest. RESULTS: After 12 weeks, the
ICQ overall score did not change signiﬁcantly in the ciclesonide
group (+0.22, p = 0.4200, two-sided), whereas statistically sig-
niﬁcantly increased (corresponding to patient-perceived worsen-
ing of the condition) in the FP group (+1.36, p = 0.0003,
two-sided). Similarly, there was no signiﬁcant change in the ICQ
domain scores in patients treated with ciclesonide, whereas with
FP signiﬁcant increases (p ≤ 0.0006, two-sided) occurred in the
domain scores “unpleasant taste” (+1.19) and “voice problems”
(+2.22). Ciclesonide was superior to FP regarding to changes in
ICQ overall score (point estimate −0.87, p = 0.0205, one-sided)
and domain score “voice problems” (point estimate −1.36, p =
0.0036, one-sided). CONCLUSION: ICS-related side-effects as
perceived by patients with moderate asthma worsened with the
relative low dose of FP 200 μg twice daily, but did not change
with ciclesonide 320 μg once daily after 12 weeks of treatment.
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OBJECTIVES: In order to measure the side effect perceptions of
patients using inhaled corticosteroids (ICS) the 57-item, 14-day
retrospective ICQ (15 domains and total score range: 0–100) was
developed. In this study we assessed the construct validity and
test-retest reliability of the ICQ in adult asthma patients.
METHODS: A total of 255 current inhaler users (non-ICS
inhaler n = 27; BDP equivalent daily low ICS dose ≤400 μg n =
61; mid dose ICS 401–800 μg n = 62; high dose ICS > 800 μg 
